Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Reexamination Certificate
2005-04-26
2005-04-26
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
C424S577000
Reexamination Certificate
active
06884413
ABSTRACT:
The present invention concerns methods of specifically inhibiting an immune response of a subject to one or more selected antigens using an immunosuppressive composition derived from a glioblastoma cell line. The method steps include obtaining a population of antigen presenting cells (APCs); loading the APC population with specific antigens (in auto-immune diseases) or using donor APCs (for transplantation); incubating the APC population with the immunosuppressive composition; and introducing the incubated cells into the subject being treated. The APCs can be monocytes, macrophages, or dendritic cells. This method causes specific inhibition of the immune response because it induces apoptosis and/or anergy in the subject's T cells specific for antigens present on the APCs, but does not affect the immune response to antigens not present on the APC surfaces. One particular embodiment of the present method is the specific inhibition of a transplant recipient's immune reaction to antigens present on the allogenic graft. A second particular embodiment of the present method is the specific inhibition of the immune response to an autoantigenic protein by a subject suffering from an autoimmune disease.
REFERENCES:
patent: 4728614 (1988-03-01), Lau
patent: 5095095 (1992-03-01), Fontana
patent: 5468481 (1995-11-01), Sharma et al.
patent: 5871728 (1999-02-01), Thomson et al.
patent: 0 155 433 (1985-09-01), None
patent: 0 159 289 (1985-10-01), None
patent: WO 9629394 (1996-09-01), None
Dix A.R et al FASEB J, 1999, V13, N.4 pp. A 610.*
Zou et al J of Acquired Immune Deficiency Syndromes and Human Retrovirology, 1997, v. 14, p. A30.*
ATCC No.: CRL-1690; 2003.
ATCC No.: CRL-2020; 2003.
ATCC No.: CRL-2365; 2003
ATCC No.: CRL-2366; 2003.
ATCC No.: HTB-16; 2003.
ATCC No.: CRL-1620; 2003.
“TGF-beta 2 Antisense Gene Therapy for Glioblastoma,”Cytokine Bulletin, Spring 1997.
Bluestone, “Transplantation Tolerance: The Next Frontier,”New Developments in Transplantation Medicine,vol.1, Spring 1994.
Elliott et al., “Suppression of High Affinity IL-2 Receptors on Mitogen activated Lymphocytes by Glioma-Derived Suppressor Factor,”J. Neuro-Oncol. 14:1-7 (1992).
Fontana et al., “Glioblastoma Cells Release Interleukin 1 and Factors Inhibiting Interleukin 2-Mediated Effects,”J. Immunol. 132:1837-1844 (1984).
Mapstone et al., “Expression of Platelet-Derived Growth Factors, Transforming Growth Factors, androsGene in a Variety of Primary Human Brain Tumors,”Neurosurg. 28216-222 (1991).
Marquardt et al., “Complete Amino Acid Sequence of Human Transforming Growth Factor Type Beta 2,”J. Biol. Chem. 262:12127-12131 (1987).
Morford et al., Apoptotic Elimination of Peripheral T Lymphocytes in Patients with Primary Intracranial Tumors,J. Neurosurg. 91:935-946 (1999).
Pisetsky, “11. Systemic Lupus Erythematosus. A. Epidemiology, Pathology, and Pathogenesis,” inPrimer on Rheumatic Diseases, pp. 100-105 (1977, v1.
Schwyzer et al., “Partial Purification and Biochemical Characterization of a T Cell Suppressor Factor Produced by Human Glioblastoma Cells,”J. Immunol. 134:1003-1009 (1985).
Zou et al., “Human Glioma-Induced Immunosuppression Involves Soluble Factor(s) that Alters Monocyte Cytokine Profile and Surface Markers,”J. Immunol. 162:4882-4892 (1999).
Chougnet Claire
Coligan John E.
Shearer Gene M.
Zuo Jian-Ping
Belyavskyi Michail
Chan Christina
Klarquist & Sparkman, LLP
The United States of America as represented by the Department of
LandOfFree
Induction of antigen-specific unresponsiveness by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Induction of antigen-specific unresponsiveness by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Induction of antigen-specific unresponsiveness by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3424632